Harrow Health Inc (HROW)
Harrow, Inc. is a U.S.-based eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic products. The company operates through two segments, Branded and ImprimisRx, and markets a range of prescription and specialty eye-care therapies, including compounded medications and branded ophthalmic treatments. Its portfolio includes products such as IHEEZO, VEVYE, ZERVIATE, BYQLOVI, ILEVRO, NEVANAC, BYOOVIZ, OPUVIZ, VIGAMOX, MAXIDEX, FLAREX, TRIESENCE, NATACYN, TOBRADEX ST, VERKAZIA, and FRESHKOTE. Harrow was founded in 1998, is headquartered in Nashville, Tennessee, and changed its name from Harrow Health, Inc. in September 2023. The listed security is common stock on NASDAQ under the symbol HROW.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HROW
|
$52.11
|
14.9% Upside
|
Fair
|
$67.75
|
49.4% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-111.4x
|
58.0x
|
6.2x
|
1.657 B
|
1.871 B
|
15.4%
|
75.9%
|
3.5
|
—
|
-95.5%
|
